Register Your Interest
English
Lorem ipsum dolor sit amet consectetur. Nibh diam vitae quisque egestas eu nulla risus. In enim in nisl natoque. Accumsan a sit feugiat amet imperdiet vel vel.
View More
Hereditary Haemorrhagic Telangiectasia (HHT) is a rare, severely debilitating and potentially life-threatening condition that affects blood vessel formation, affecting multiple body systems and organs. Currently there are no specific therapies available for patients with HHT. That’s why we’re conducting the DIAMOND Trial.
The DIAMOND Trial is phase 1/2 (first-in-human) study testing a potential new treatment for HHT. The study treatment is an antibody that has been designed to restore an important cell signalling pathway. This study is focused on understanding the safety and tolerability of this potential new treatment.
We’re looking for people living with HHT to take part in this study. Your involvement in this study could help improve how we treat HHT, globally and for future generations to come.
Screening, 4-night stay and 4 clinic visits over approximately 4 weeks
Reimbursement if you complete all scheduled visits will be up to $4,250
18 years old and older
All genders welcome
Have a clinical diagnosis of HHT
Individuals who require blood thinning medication are not suitable for this study
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}